Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences
On April 15-16, 2022 the 6th International Conference on Pharmaceutics and Advanced Drug Delivery Systems will welcome you to Paris, France. Pharmaceutical Science 2022 encompasses practically every aspect of knowledge, innovation, technology, and networking, with the goal of bringing academics, practitioners, and business executives together to debate the most pressing issues in pharma, biotech, and health care. Drug Discovery and Development, Pharmacovigilance and Drug Safety, Novel Drug Delivery Systems and Drug Therapy, Pharmaceutical Nanotechnology, Drug Regulatory Affairs, Pharmacology, Neuropharmacology, Nutraceuticals, Pharma Marketing, and more are all covered in this two-day program.
Theme: Pharmaceutical Science’s Most Recent Advances and Innovations
Pharmacogenomics
Neuropharmacology
Pharmacology
Pharmaceutical Marketing, Big Data, and Analytics
Digital Pharma & Multichannel Marketing
Pharmaceutical Microbiology and Biotechnology
Pharmaceutical Chemistry and Medicinal Chemistry
Biopharmaceutical
Pharmaceutical Nanotechnology
Pharmacovigilance and Drug Safety
Drug Discovery and Development
Clinical Trials and Drug Regulatory Affairs
Challenges in Drug Delivery
Advances in Drug Delivery
Nanotechnology and Drug carrier systems
Novel Drug Delivery Systems
Alternative Drug Delivery System
Peptides and Protein Drug delivery
Nutraceuticals
Analytical and Bioanalytical Techniques
Cosmeceuticals
Purpose
This is your single best opportunity to access the largest assemblage of people from the scientific community, with members from all around the world interested in learning about Pharmaceutics & Advanced Drug Delivery Systems. At this amazing event, do demos, spread information, meet with notable individuals, and create a splash with the latest research advances.
Goals
• Evidence-based practise, educational innovation, practical application, and peer-to-peer networking and cooperation are all highlighted in the conference programme.
• The conference’s objectives are to deliver transformative professional development and experience.
• Bringing together the world’s leading scientists to stimulate and advance scientific knowledge in the fields of pharmaceutics and drug delivery systems, present the most recent research findings, and promote and enhance international scientific collaborations.
• Bringing together community leaders, scientists, and policymakers to develop and expand programmatic collaborations in order to more effectively solve drug discovery and delivery issues.
Objectives
Attendees should be able to:
• Discuss emerging issues in drug development and drug delivery systems after attending this meeting.
• Discuss and apply recent pharmaceutics and drug delivery research findings.
• Disseminate the different perspectives of visionary and practical solution providers.
Who should attend?
Academicians, Researchers, Scientists from Research Institutes, Pharmaceutical
Firms, Clinical Scientists, Pharmacologists, Pharmacists, Biotechnologist,
Pharmaceutical Industrialists, Business Delegates, Healthcare Professionals, and
Pharmaceutical Entrepreneurs, Professors, Doctors, Students, and Research Scholars
from Universities and Colleges, Academicians, Researchers, Scientists from Research
Institutes, Pharmaceutical Firms, Clinical Scientists, Pharmacologists, Pharmacists,
Biotechnologist, Pharmaceutical Industrialists, Pharmaceutical Industrialist.
Pharmaceuticals is one of the most significant and important fields for human welfare, as well as one of the world’s major economies. The entire value of the pharmaceutical sector exceeds $5 trillion. When compared to the 1920s, it has grown by a factor of a thousand. From USD 1,179.20 billion in 2016 to USD 1,669.40 billion in 2021, the total market value of drug delivery technology is predicted to rise at a CAGR of 7.2 percent.
In 2017, global prescription pharmaceutical sales were $774 billion, while in 2018, they were $811 billion. Profits from prescription drug sales are expected to exceed one trillion dollars by 2022. The current state of the pharmaceutical industry is as follows: As a result of new innovative research, demand for new medicines, and new regulatory laws and standards, the pharmaceutical business is undergoing considerable transformations. Countries including Russia, the United Kingdom, the United States, China, and India have boosted their need for generic medications in recent years, and developing drugs for rare diseases has become increasingly popular.
The global pharmaceutical manufacturing industry is expected to develop at a compound annual growth rate (CAGR) of 13.74 percent from 2020 to 2027. The continued expenditures of pharmaceutical and outsourcing businesses in expanding their manufacturing facilities have had a positive impact on market growth.
AstraZeneca, for example, invested USD 133.0 million in February 2020 to expand its manufacturing facilities in Australia. In December 2019, PCI Pharma Services, a global outsourcing solution provider, updated its Tredegar factory in the United Kingdom to expand its high-potency drug research and production capabilities.
The intrusion has improved the data management process.
Key players in the pharma market:
Johnson & Johnson – $56.1bn.
Pfizer – $51.75bn.
Roche – $49.23bn.
Novartis – $47.45bn.
Merck & Co. – $46.84bn.
GlaxoSmithKline – $44.27bn.
Sanofi – $40.46bn.
AbbVie – $33.26bn.
Future projections about pharma sector:
The pharmaceutical industry’s overall revenue is expected to double in real terms between 2017 and 2060. Certain markets would grow at a breakneck pace. The Chinese pharmaceutical business, for example, will grow fourfold between now and 2060, while the European market will grow more slowly. The rare disease segment of the pharmaceutical sector will be a major growth driver. New discoveries will expand the pharmaceutical industry’s size and growth, which will help society’s health and well-being. Long-term growth is projected to be driven by new therapeutics such as nucleic acid medications and implantable devices.
R&D in France:
France is the second-biggest European market for pharmaceuticals and one of the world’s largest users. Between 2000 and 2010, the pharmaceutical industry in France increased by 17.9%, compared to 6.1 percent in the industrial sector. According to Philippe Archinard, Ph.D., CEO of Transgene and chairman of Lyon Biopôle, “this performance can be explained by significant scientific, industrial, and economic advantages, as well as the vitality of its participants of all sizes.”
However, according to Global Data, the French pharmaceutical market is expected to grow by just 0.7% CAGR from $46.2 billion in 2014 to $48.2 billion by 2022, mostly due to an increasing focus on generic drugs. Despite the negative impact of generics, France’s pharmaceutical market will be boosted by a number of factors, including an aging population, tax incentives, a substantial skilled workforce and high public healthcare expenditure.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
